No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGDm | 23 | 19 | 19 | 19 | 19 | N/A | N/A | N/A |
| Operating profit | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SGDm | 8 | 6 | 3 | 4 | 8 | N/A | N/A | N/A |
| EPS reported | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and colonoscopies, in addition to providing general surgical services with a notable focus on colorectal issues. Their expertise further extends to treating a variety of conditions, including haemorrhoids, anal fissures, hernias, anal abscesses, cholecystitis, anal fistulas, appendicitis, colorectal and gastric cancers, lipomas, and cysts, utilizing advanced techniques like vein laser vascular therapy and laparoscopy. Moreover, the company offers extensive orthopedic services. These address concerns such as joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, tenosynovitis, tunnel syndrome, and various wounds or lumps. Surgical interventions include joint replacements, arthroscopic procedures, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, and fracture management, supported by orthobiologic injections. Beyond clinical care, the company provides comprehensive home care services, encompassing medical, nursing, physiotherapy, speech, occupational therapy, and ambulance support. Their community health initiatives include health screenings, management of acute and chronic conditions, pre-employment check-ups, and participation in public health schemes such as the 'swab and send home' program, the community health assist scheme, and COVID-19 testing. To support accurate diagnosis, a full array of diagnostic tests is available, including blood work, X-rays, ultrasounds, CT scans, and MRIs. The company was founded in Singapore in 2015, where it continues to be headquartered.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
HC Surgical Specialists Limited (1B1.SI)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and colonoscopies, in addition to providing general surgical services with a notable focus on colorectal issues. Their expertise further extends to treating a variety of conditions, including haemorrhoids, anal fissures, hernias, anal abscesses, cholecystitis, anal fistulas, appendicitis, colorectal and gastric cancers, lipomas, and cysts, utilizing advanced techniques like vein laser vascular therapy and laparoscopy. Moreover, the company offers extensive orthopedic services. These address concerns such as joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, tenosynovitis, tunnel syndrome, and various wounds or lumps. Surgical interventions include joint replacements, arthroscopic procedures, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, and fracture management, supported by orthobiologic injections. Beyond clinical care, the company provides comprehensive home care services, encompassing medical, nursing, physiotherapy, speech, occupational therapy, and ambulance support. Their community health initiatives include health screenings, management of acute and chronic conditions, pre-employment check-ups, and participation in public health schemes such as the 'swab and send home' program, the community health assist scheme, and COVID-19 testing. To support accurate diagnosis, a full array of diagnostic tests is available, including blood work, X-rays, ultrasounds, CT scans, and MRIs. The company was founded in Singapore in 2015, where it continues to be headquartered.